ADVANCED CANCER IMMUNOTHERAPY
Incysus was formed to develop commercially viable and effective immune based therapies for the treatment of cancer
Incysus Therapeutics, Inc. ("Incysus") is a biotechnology company advancing a unique and innovative approach towards the treatment of cancers.
We are focused on delivering a novel off-the-shelf product for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, our technology addresses the challenges that immunotherapies face when targeting cold, low mutation cancers.
Incysus received clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to test the safety and activity of an allogeneic donor γδ T cell infusion for cancer immunotherapy in a Phase I trial (NCT03533816). This is an initial step towards developing 'off-the-shelf' cell therapies with γδ T cells. Incysus has also received FDA clearance of a second IND allowing for the initiation of a Phase I clinical trial of our novel Drug Resistant Immunotherapy (DRI) platform (NCT04165941). This trial for the treatment of patients with newly-diagnosed glioblastoma (GBM) is the first genetically modified γδ T cell product candidate cleared to enter the clinic.
Our unique DRI technology offers an elegant approach to immuno-oncology that deals with multiple mechanisms of tumor resistance and immunosuppression. We believe this approach will lead to the development of more effective treatments for patients with difficult-to-treat solid tumor cancers.